LIPOSOMAL FORMULATIONS OF ANTHRACYCLINE AGENTS AND CYTIDINE ANALOGS
    8.
    发明申请
    LIPOSOMAL FORMULATIONS OF ANTHRACYCLINE AGENTS AND CYTIDINE ANALOGS 有权
    蒽醌类药物和细胞模拟物的脂质体制剂

    公开(公告)号:US20120009252A1

    公开(公告)日:2012-01-12

    申请号:US13237807

    申请日:2011-09-20

    摘要: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

    摘要翻译: 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素,多柔比星和伊达比星组,而优选的胞苷类似物选自阿糖胞苷,吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。

    Liposomal formulations of anthracycline agents and cytidine analogs
    9.
    发明授权
    Liposomal formulations of anthracycline agents and cytidine analogs 有权
    蒽环类药物和胞苷类似物的脂质体制剂

    公开(公告)号:US08431806B2

    公开(公告)日:2013-04-30

    申请号:US13237807

    申请日:2011-09-20

    IPC分类号: A61K9/127

    摘要: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

    摘要翻译: 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素,多柔比星和伊达比星组,而优选的胞苷类似物选自阿糖胞苷,吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。

    Liposomal formulations of anthracycline agents and cytidine analogs
    10.
    发明授权
    Liposomal formulations of anthracycline agents and cytidine analogs 有权
    蒽环类药物和胞苷类似物的脂质体制剂

    公开(公告)号:US08022279B2

    公开(公告)日:2011-09-20

    申请号:US11587112

    申请日:2005-04-22

    IPC分类号: A61K9/127

    摘要: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

    摘要翻译: 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素,多柔比星和伊达比星组,而优选的胞苷类似物选自阿糖胞苷,吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。